<DOC>
	<DOCNO>NCT01839526</DOCNO>
	<brief_summary>No investigational drug administer study treatment Fabry disease . This multicenter , multinational , non-treatment , cross-sectional study young male patient Fabry disease yet initiate interventional treatment disease . The study consist screen visit ( ) , clinical investigation visit ( ) , follow-up phone contact . The objective study : - To document renal function Fabry disease manifestation across age treatment-naïve , young male patient Fabry disease . - To provide reference group comparison interventional clinical trial Fabry disease . The duration patient 's participation study , inclusive screen visit follow-up phone contact , approximately 12 week .</brief_summary>
	<brief_title>A Study Renal Function Treatment-naïve , Young Male Patients With Fabry Disease</brief_title>
	<detailed_description>Patients meet eligibility criterion base screen assessment schedule return clinic assessment renal function disease-related parameter , may schedule one clinical investigation visit . The clinical investigation visit ( ) schedule renal cardiac assessment occur require medication washout ( see exclusion criterion ) ; procedure may perform either medication washout , discretion investigator . Up 100 patient enrol study , include minimum 15 patient follow age group ( base age screen ) : 5 11 year , 12 17 year , 18 25 year . All patient encourage enroll Fabry Registry ( NCT00196742 ) continue follow-up completion study .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>The patient and/or parent/legal guardian willing able provide sign informed consent . If patient age consent per local guideline , willing provide assent , deem able . The patient must confirm diagnosis Fabry disease document leukocyte αgalactosidase A ( αGAL ) &lt; 4 nmol/hr/mg leukocyte ( preferred assay ; result central laboratory ) . If leukocyte αGAL activity assay difficult obtain , patient may enrol base documented plasma αGAL &lt; 1.5 nmol/hr/mL ( result central laboratory ) , agreement Genzyme Medical Monitor . Patient receive prior treatment enzyme replacement therapy ( ERT ) oral pharmacological chaperone therapy Fabry disease . Patient receive investigational drug within 30 day screen visit . Patient receive follow medication clinically unable unwilling temporarily discontinue treatment medication indicate washout period prior renal function assessment completion assessment : Angiotensin convert enzyme inhibitor angiotensin receptor blocker ( 6 week washout ) ; Nonsteroidal antiinflammatory drug ( 3 day washout ) . NOTE : Patients chronic dialysis kidney transplant require discontinue medication renal function assessment perform patient . Patient contraindication mention label iohexol . NOTE : patient eGFR &lt; 30 mL/min/1.73m^2 patient chronic dialysis kidney transplant may enrol irrespective contraindication iohexol iGFR measure patient . Patient medical condition extenuate circumstance , opinion Investigator , could interfere patient 's ability complete study procedure , interpretation study result ( e.g. , diabetes mellitus ) . The patient and/or parent legal guardian , opinion Investigator , unable adhere requirement study .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Fabry disease</keyword>
</DOC>